### WAVEDATA

Special points of interest

This bulletin is free to Interested people in Pharma & Healthcare

Please send names of new subcribers to Jackie@wavedata.co.uk

If you have articles, comments or story ideas, please send them to the email above

www.wavedata.co.uk

## **Inside this issue**

UK plans to fast track access to drugs

Unapproved drug given to young boy

New technology for science firms

Side effects in children need to be reported

Forthcoming events 2014

PRICE-WATCH ......UK Memantine drops below 90% discount line

WaveData — Top ten searched products and 3 month's average prices

# Commercial Bulletin

MONTHLY SERVICE

MARCH 2014

# UK plans to fast track access to drugs

Plans are expected to be announced at any time for the UK to launch early access to medicines.

People with serious illnesses for where there is no current treatment would be offered the early access to the drugs.

The scheme will be launched in April and will be overseen by the MHRA.

To read more:

http://www.bbc.co.uk/news/health-26553301

## Unapproved drug given to young boy

A sick 7 year old boy could be given medicines that could save his life.

Chimerix announced that the company is starting a new trial and JH will be the first patient to participate.

The drug is yet to be approved by the US FDA.

To read more:

http://www.heraldsun.com/news/showcase/x1001076830/St-Jude-officials-7-year-old-relatively-stable-after-receiving-Chimerix-drug

## New technology for science firms

New technology approaches in science companies could benefit commercial operations, with cloud-based business intelligence applications and storage, embedded analytics and systems integration.

This will therefore lower costs for the Pharma companies and improve the patient's outcome

The new technologies could make huge changes to the overall healthcare system within the next three years.

To read more:

http://www.pharmpro.com/news/2014/03/study-technology-drives-breakthrough-approaches-life-sciences-commercial-operations



# Side effects in children need to be reported

The MHRA say that side effects experienced in young children are not reported to their GP or a pharmacist.

Parents in London are least likely in the UK to report a reaction to their children's medication.

Research implies that only 10%-15% out of the entire population report serious side ef-

It is important the side effects are reported using the yellow card system.

To read more: http://news.uk.msn.com/call-to-report-drug-side-effects-1

MONTHLY SERVICE PAGE 3

# Forthcoming events 2014

Organizer	Date	Venue	Link or Email	
PharmaGora	29-30 March 2014	Paris, France	http://www.pharmagora.com/	
			Jan San San San San San San San San San S	
Supply Chain Conference.	Wednesday 2nd and Thursday 3rd April 2014	near Tower Bridge in cen- tral London	http://www.esc-lon.co.uk/en/attendees.aspx	
12th EGA International Biosimilar	0.4.4. ".0044	T. T		
Medicines Conference	3-4 April 2014	The Tower Hotel, London	www.egagenerics.com	
MHRA Quality of Medicines	9th April 2014	London	email.support@mhra.gsi.gov.uk	
Nice	13 - 14 May 2014	The ICC, Birmingham	http://ow.ly/rPT8M	
50th DIA Annual Meeting	Jun-14	San Diego	http://www.ccra.org.uk/Meetings/FutureEvents.asp	
CPHI/ICSE	Oct-14	Paris	http://www.ccra.org.uk/Meetings/FutureEvents.asp	
AAPS Annual Meeting & Exposition	Nov-14	San Diego	http://www.ccra.org.uk/Meetings/FutureEvents.asp	



## PRICE WATCH ..... UK



# Memantine drops below 90% discount line

Double-digit price falls were apparent among our 'fast movers' this month, including bicalutamide 50mg, desloratadine 5mg, memantine 10mg and rizatriptan 10mg (see figure1). Both memantine and rizatriptan were added to category M of the Drug Tariff of pharmacy reimbursement prices in January, having been launched in may and August last year.

To see more go to http://www.wavedata.co.uk/newinfo.asp and view our article from this month's Generics Bulletin.

## WaveData

Subscribe to the industry's comprehensive source of news and analysis.

www.generics-bulletin.com

## WaveData — Top ten searched products and 3 month's average prices

According to WaveData, these were the most commonly investigated products in searches of the online pricing data Wavedata Live at http://www.wavedata.net

Both uk and pi prices were viewed for each product, giving some indication of where the focus was to February 2014

Product	2013 12	2014 01	2014 02
Lansoprazole Caps 15mg 28	£0.51	£0.50	£0.48
Co-Amoxiclav Tabs 250mg/125mg 21	£3.43	£3.36	£3.34
Co-Amoxiclav Tabs 500mg/125mg 21	£6.44	£6.48	£5.89
Gabapentin Caps 300mg 100	£11.03	£9.85	£8.80
Fluoxetine Caps 20mg 30	£0.45	£0.47	£0.53
Hydrocortisone Tabs 10mg 30	£45.54	£46.83	£48.52
Atorvastatin Tabs 40mg 28	£1.08	£1.04	£1.12
Metformin Tabs 500mg 28	£0.26	£0.35	£0.53
Alendronate Tabs 70mg 4	£0.55	£0.63	£0.72
Amitriptyline Tabs 10mg 28	£0.29	£0.30	£0.31



This bulletin now goes out to 3600 plus people, and it is growing each month.

If you would like to add or suggest any articles/comments, please let me know by the 16th April 2014, as I will be issuing the next one on the 23rd April 2014

If you have any colleagues who would like to receive this, please let them know about it.

You can view all copies of the Bulletin at

http://www.wavedata.co.uk/newinfo.asp

Jackie Moss WaveData Ltd

E-mail: Jackie@wavedata.co.uk

07968 815192

Twitter @wavedata